Drug Deal Disclosure Act
Sen. Wyden Introduces Bill to Force Disclosure of Trump Administration Drug Pricing Deals
The Drug Deal Disclosure Act is currently in the early stages of the legislative process. It was recently introduced in the Senate and sent to the Committee on Health, Education, Labor, and Pensions for review. There are no upcoming votes scheduled at this time.
Legislative Progress
This bill is a partisan effort to investigate the current administration's private deals. Without support from the majority party, it is unlikely to move past the committee stage.
Key Points
Impact Analysis
Personal Impact
Life & Work
Small businesses that provide health insurance to employees could be indirectly affected. If the transparency reveals that drug pricing deals are raising or lowering costs in ways that flow through to employer health plans, that information could influence future policy and business decisions about coverage. However, this is an indirect effect through the broader transparency goal rather than a direct impact.
Programs
Disabilities
Milestones
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
3 articlesSenators introduce bill to force disclosure of Trump administration drug deals
Sen. Ron Wyden and 18 fellow Senate Democrats introduced the Drug Deal Disclosure Act to require the disclosure of drug pricing agreements between the Trump administration and pharmaceutical companies. The bill would direct HHS to release contracts and communications within 30 days of enactment.
Democrats warn TrumpRx website could cost consumers more
A new report from congressional Democrats warns that the TrumpRx website directs Americans to brand-name drugs rather than cheaper generics. The findings have fueled a legislative push to force the administration to reveal the private deals made with pharmaceutical companies.
TrumpRx launch features discounted prices for 40 medications
The Trump administration launched TrumpRx, an online platform for discounted prescription drugs. While the administration touts 'historic' price reductions, experts and lawmakers are questioning the lack of transparency regarding the deals struck with companies like Pfizer and Eli Lilly.
Source Information
Document Type
Congressional Bill
Official Title
Drug Deal Disclosure Act
Data Sources
Sponsor
Cosponsors
(18)Analysis generated by AI. Always verify with official sources.